Monthly Archives: October 2022

The Department of Molecular Genetics is administered from the Medical Sciences Building and has nearly 100 faculty members whose labs are located within the Medical Science Building, the Best Institute, the Donnelly Centre for Cellular and Biomolecular Research, the FitzGerald Building, the Hospital for Sick Children, Mount Sinai Hospital, the Ontario Institute for Cancer Research, and Princess Margaret Hospital.

The Master of Science and Doctor of Philosophy programs in Molecular Genetics offer research training in a broad range of genetic systems from bacteria and viruses to humans. Research projects include DNA repair, recombination and segregation, transcription, RNA splicing and catalysis, regulation of gene expression, signal transduction, interactions of host cells with bacteria and viruses, developmental genetics of simple organisms (worms and fruit flies) as well as complex organisms (mice), molecular neurobiology, molecular immunology, cancer biology and virology, structural biology, and human genetics and gene therapy.

Students may also be interested in the combined degree program inMedicine, Doctor of / Doctor of Philosophy (MD/PhD).

See video: Explore Graduate Programs at the Faculty of Medicine.

More:
Molecular Genetics School of Graduate Studies - University of Toronto

Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:33646.

PubMed PubMed Central Article Google Scholar

Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299312.

PubMed Article Google Scholar

Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:170012.

Article Google Scholar

American Psychiatric Association DS, Association AP, Others. Diagnostic and statistical manual of mental disorders: DSM-5, Vol. 5. Washington, DC: American Psychiatric Association; 2013.

Book Google Scholar

Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, et al. Augmentative pharmacological strategies in treatment-resistant major depression: a comprehensive review. Int J Mol Sci. 2021;22:13070.

CAS PubMed PubMed Central Article Google Scholar

Zhuo C, Li G, Lin X, Jiang D, Xu Y, Tian H, et al. The rise and fall of MRI studies in major depressive disorder. Transl Psychiatry. 2019;9:335.

PubMed PubMed Central Article Google Scholar

Nolan M, Roman E, Nasa A, Levins KJ, OHanlon E, OKeane V, et al. Hippocampal and amygdalar volume changes in major depressive disorder: a targeted review and focus on stress. Chronic Stress. 2020;4:2470547020944553.

PubMed PubMed Central Article Google Scholar

Hellewell SC, Welton T, Maller JJ, Lyon M, Korgaonkar MS, Koslow SH, et al. Profound and reproducible patterns of reduced regional gray matter characterize major depressive disorder. Transl Psychiatry. 2019;9:176.

PubMed PubMed Central Article Google Scholar

Schmaal L, Pozzi E, Ho TC, van Velzen LS, Veer IM, Opel N, et al. ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing. Transl Psychiatry. 2020;10:172.

PubMed PubMed Central Article Google Scholar

Stockmeier CA, Rajkowska G. Cellular abnormalities in depression: evidence from postmortem brain tissue. Dialogues Clin Neurosci. 2004;6:18597.

PubMed PubMed Central Article Google Scholar

Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013;16:6982.

CAS PubMed Article Google Scholar

Li J, Seidlitz J, Suckling J, Fan F, Ji GJ, Meng Y, et al. Cortical structural differences in major depressive disorder correlate with cell type-specific transcriptional signatures. Nat Commun. 2021;12:1647.

CAS PubMed PubMed Central Article Google Scholar

Prentner R. Consciousness: a molecular perspective. Philosophies. 2017;2:26.

Article Google Scholar

Sohn E. Decoding the neuroscience of consciousness. Nature. 2019;571:S25.

CAS PubMed Article Google Scholar

Shadrina M, Bondarenko EA, Slominsky PA. Genetics factors in major depression disease. Front Psychiatry. 2018;9:334.

PubMed PubMed Central Article Google Scholar

Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18:497511.

Article Google Scholar

Viktorin A, Meltzer-Brody S, Kuja-Halkola R, Sullivan PF, Landn M, Lichtenstein P, et al. Heritability of perinatal depression and genetic overlap with nonperinatal depression. Am J Psychiatry. 2016;173:15865.

PubMed Article Google Scholar

Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021;24:95463.

CAS PubMed PubMed Central Article Google Scholar

Noh K, Park JC, Han JS, Lee SJ. From bound cells comes a sound mind: the role of neuronal growth regulator 1 in psychiatric disorders. Exp Neurobiol. 2020;29:110.

PubMed PubMed Central Article Google Scholar

Dennis EL, Jahanshad N, Braskie MN, Warstadt NM, Hibar DP, Kohannim O, et al. Obesity gene NEGR1 associated with white matter integrity in healthy young adults. Neuroimage. 2014;102:54857.

CAS PubMed Article Google Scholar

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, et al. The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. J Neural Transm. 2019;126:3545.

CAS PubMed Article Google Scholar

Zhang YQ, Lin WP, Huang LP, Zhao B, Zhang CC, Yin DM. Dopamine D2 receptor regulates cortical synaptic pruning in rodents. Nat Commun. 2021;12:6444.

CAS PubMed PubMed Central Article Google Scholar

Wagnon JL, Briese M, Sun W, Mahaffey CL, Curk T, Rot G, et al. CELF4 regulates translation and local abundance of a vast set of mRNAs, including genes associated with regulation of synaptic function. PLoS Genet. 2012;8:e1003067.

CAS PubMed PubMed Central Article Google Scholar

Shen Y, Zhang C, Xiao K, Liu D, Xie G. CELF4 regulates spine formation and depression-like behaviors of mice. Biochem Biophys Res Commun. 2022;605:3944.

CAS PubMed Article Google Scholar

Starnawska A, Tan Q, Soerensen M, McGue M, Mors O, Brglum AD, et al. Epigenome-wide association study of depression symptomatology in elderly monozygotic twins. Transl Psychiatry. 2019;9:214.

CAS PubMed PubMed Central Article Google Scholar

Chan RF, Turecki G, Shabalin AA, Guintivano J, Zhao M, Xie LY, et al. Cell typespecific methylome-wide association studies implicate neurotrophin and innate immune signaling in major depressive disorder. Biol Psychiatry. 2020;87:43142.

CAS PubMed Article Google Scholar

Roberson-Nay R, Lapato DM, Wolen AR, Lancaster EE, Webb BT, Verhulst B, et al. An epigenome-wide association study of early-onset major depression in monozygotic twins. Transl Psychiatry. 2020;10:301.

CAS PubMed PubMed Central Article Google Scholar

Litke C, Bading H, Mauceri D. Histone deacetylase 4 shapes neuronal morphology via a mechanism involving regulation of expression of vascular endothelial growth factor D. J Biol Chem. 2018;293:8196207.

CAS PubMed PubMed Central Article Google Scholar

Kim MS, Akhtar MW, Adachi M, Mahgoub M, Bassel-Duby R, Kavalali ET, et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J Neurosci. 2012;32:1087986.

CAS PubMed PubMed Central Article Google Scholar

Shi Y, Wang Q, Song R, Kong Y, Zhang Z. Non-coding RNAs in depression: promising diagnostic and therapeutic biomarkers. EBioMedicine. 2021;71:103569.

CAS PubMed PubMed Central Article Google Scholar

Dwivedi Y. MicroRNAs in depression and suicide: recent insights and future perspectives. J Affect Disord. 2018;240:14654.

CAS PubMed PubMed Central Article Google Scholar

Deussing JM, Jakovcevski M. Histone modifications in major depressive disorder and related rodent models. Adv Exp Med Biol. 2017;978:16983.

CAS PubMed Article Google Scholar

Homorogan C, Nitusca D, Seclaman E, Enatescu V, Marian C. Uncovering the roles of microRNAs in major depressive disorder: from candidate diagnostic biomarkers to treatment response indicators. Life. 2021;11:1073.

CAS PubMed PubMed Central Article Google Scholar

Xu N, Li AD, Ji LL, Ye Y, Wang ZY, Tong L. miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. Eur J Histochem. 2019;63:3008.

PubMed Central Article Google Scholar

Scott HL, Tamagnini F, Narduzzo KE, Howarth JL, Lee YB, Wong LF, et al. MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci. 2012;36:29418.

PubMed PubMed Central Article Google Scholar

Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:5463.

CAS PubMed Article Google Scholar

Kaltenboeck A, Harmer C. The neuroscience of depressive disorders: a brief review of the past and some considerations about the future. Brain Neurosci Adv. 2018;2:2398212818799269.

PubMed PubMed Central Article Google Scholar

Pan JX, Xia JJ, Deng FL, Liang WW, Wu J, Yin BM, et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study. Transl Psychiatry. 2018;8:130.

PubMed PubMed Central Article Google Scholar

Fogaa MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions. Front Cell Neurosci. 2019;13:87.

PubMed PubMed Central Article Google Scholar

Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383406.

CAS PubMed Article Google Scholar

Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:7590.

CAS PubMed PubMed Central Article Google Scholar

Shin C, Kim YK. Ketamine in major depressive disorder: mechanisms and future perspectives. Psychiatry Investig. 2020;17:18192.

CAS PubMed PubMed Central Article Google Scholar

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:4816.

CAS PubMed PubMed Central Article Google Scholar

Edinoff AN, Odisho AS, Lewis K, Kaskas A, Hunt G, Cornett EM, et al. Brexanolone, a GABAA modulator, in the treatment of postpartum depression in adults: a comprehensive review. Front Psychiatry. 2021;12:699740.

PubMed PubMed Central Article Google Scholar

Prez de la Mora M, Borroto-Escuela DO, Crespo-Ramrez M, Rejn-Orantes JDC, Palacios-Lagunas DA, Martnez-Mata MK, et al. Dysfunctional heteroreceptor complexes as novel targets for the treatment of major depressive and anxiety disorders. Cells. 2022;11:1826.

PubMed PubMed Central Article Google Scholar

Reeves KC, Shah N, Muoz B, Atwood BK. Opioid receptor-mediated regulation of neurotransmission in the brain. Front Mol Neurosci. 2022;15:919773.

CAS PubMed PubMed Central Article Google Scholar

Puryear CB, Brooks J, Tan L, Smith K, Li Y, Cunningham J, et al. Opioid receptor modulation of neural circuits in depression: what can be learned from preclinical data? Neurosci Biobehav Rev. 2020;108:65878.

PubMed Article Google Scholar

Pecia M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta JK. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24:57687.

PubMed Article Google Scholar

Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharm Ther. 2019;201:5176.

CAS Article Google Scholar

Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, et al. It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry. 2015;20:193200.

CAS PubMed PubMed Central Article Google Scholar

Continued here:
Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com

A team of LSU researchers has developed a way to determine which drug therapies work best against an individual's unique type of cancer, possibly providing a way to find cures more quickly and make treatment more affordable.

The interdisciplinary team includes researchers from the School of Veterinary Medicine, College of Science, College of Engineering and the Center for Computation & Technology. It created CancerOmicsNet, a new drug discovery engine run by artificial intelligence.

Using algorithms originally designed to map complex social networks, like those utilized by Facebook, researchers generated three-dimensional graphs of molecular datasets that include cancer cell lines, drug compounds and interactions among proteins inside the human body.

The graphs are then analyzed and interconnected by AI, forming a much clearer picture of how a specific cancer would respond to a specific drug.

Dr. Michal Brylinski, associate professor of computational biology at LSU, said that the team used established datasets to train the CancerOmicsNet engine into using artificial intelligence.

"Once its trained, then you can ask for something that you dont know and this is the input data," he said. "So you ask what inhibitor you think is going to be effective against this cancer and then AI makes a prediction. Thats the implication to unseen data and then something like that goes to a wet lab and we can validate it.

Wet lab research was conducted by researchers at the LSU School of Veterinary Medicine and led by associate professor of research Brent Stanfield.

They developed the AI algorithm and everything, so our role in the study is just to be the practical applications of the technology," Stanfield said. "They developed the algorithm, identified the drugs and then we tested the drugs in our high-capacity systems to demonstrate their efficacy to kill cancer cells.

Researchers studied notoriously aggressive breast, prostate and pancreatic cell lines to train the AI to recognize connections between specific cancers and cancer drugs that control the production of the enzyme kinase within the body.

Kinase acts as a biological catalyst for cell communication and cell growth. Using drugs that lower kinase activity can suppress the growth of cancerous cells.

Brylinski said the research team used CancerOmicsNet to pick out six combinations of cancer cell lines with the drugs likely to be the most toxic to their gene expression profile and tested them, with encouraging results.

According to acceptable criteria, four out of six worked and this success rate is extremely high because if you just picked up six random drugs and say those drugs are going to work on this cancer, then theyre probably not going to work on that cancer," he said. "Four out of six was very encouraging and this is where we stand right now."

Using CancerOmicsNet like molecular speed dating, the AI can help researchers quickly match cancer cell lines with the drugs likely to be the most toxic to their growth and genetic profile.

Brylinski said knowledge gained through CancerOmicsNet can help overcome the challenge of determining how effective a particular kinase-inhibiting drug could be in the future.

The ultimate goal, he said, is to expand their research to potentially apply it in clinical settings.

"If we have a patient with a certain cancer, they can do a biopsy and then they can profile this cancer with respect to gene expression, genetic mutations and everything," Brylinski said. "Then they can input that data to CancerOmicsNet and it can suggest some therapy for this particular cancer and say this drug could be effective and 'another drug could not be effective.'

The effectiveness of various cancer drugs was initially believed to be tied to molecular consistency, the idea that cancer treatment should be targeted to a specific to a location in the body.

Michelle Collins, dean of the College of Nursing and Health at Loyola University New Orleans and a scientist not involved in the LSU research, said CancerOmicsNet is an example of how our current medical understanding of cancer treatment meets advances in genetic studies and AI.

When cancer drugs first came out, they were one size fits all and werent really tailored to the individual and so you see the medications work better on some people than others," she said. "And with the advent of genetics and genomics, which are the future of medicine, were now going to be able to tailor treatments to the patient and not just in oncology.

Collins said she sees CancerOmicsNet being extremely beneficial to oncological studies and treatment in the future.

I think it has the potential to really revolutionize the field of oncology, because well be able to treat people with medication that is more timely tailored to them," she said. "All of that is good if youre a patient with cancer.

Brylinksi said that the ability to treat cancer with a more direct, focused clinical approach makes him excited to see how CancerOmicsNet develops over time.

"I dont know if were going to make some major breakthrough in oncology any time soon, but were contributing pieces where if enough people are doing this, the whole field is moving forward towards the goal of improving human health," he said. "Were very happy that we can make some contribution, which might not be a huge breakthrough down the road, but definitely something that is useful to improving human health and thats really cool actually.

View post:
Can artificial intelligence help identify best treatments for cancers? LSU researchers say yes - The Advocate

VILMORIN & CIE

*On a like-for-like basis.

Financial statements for fiscal year 2021-2022:Vilmorin & Cie once again demonstrates the resilience of its model by achieving solid commercial and financial performances

The consolidated financial statements for 2021-2022, closing on June 30, 2022, were approved by the Vilmorin&Cie Board at its meeting of October 12, 2022. The Statutory Auditors have examined this annual financial information with no particular comments or reservations to make in their conclusions.

In millions of euros

2021-2022

2020-2021

Variationwith current datavs. 2020-2021

Sales for the year

1,587.2

1,476.6

+7.5%

EBITDA

392.1

367.2

+24.9 M

Operating income

136.3

127.4

+8.9 M

Income from associated companies

17.9

26.3

-8.4 M

Financial result

-33.4

-46.9

+13.5 M

Income taxesOf which:

Current taxes

Deferred taxes

-25.4

-22.9-2.5

-13.4

-21.58.1

-12.0 M

-1.4 M-10.6 M

Consolidated net income

95.4

93.4

+2.0 M

Group share of net income

92.2

92.3

-0.1 M

Vilmorin & Cie's consolidated financial information has been established, at the close of fiscal year 2021-2022, in compliance with the IFRS reference (International Financial Reporting Standards) as applied by the European Union on June 30,2022. Consolidated sales, corresponding to revenue from ordinary activities for fiscal year 2021-2022 came to 1,587.2 million euros, an increase of 7.5% with current data, and 6.2% on a like-for-like basis compared with 2020-2021. In spite of a general context that was destabilized by the Russian-Ukrainian conflict, Vilmorin & Cie managed to exceed its objective for growth in consolidated sales as revised at the end of the third quarter of the fiscal year (i.e. growth of around 5% on a comparable basis)1.

After taking into account the cost of destruction and depreciation of inventory, the margin on the cost of goods stood at 48.6%, a decrease of 0.7 percentage points compared with 2020-2021.

Net operating charges came to 635.2 million euros, as opposed to 600.6million euros on June30, 2021.

In compliance with its strategic orientations, Vilmorin & Cie pursued its research programs, both in terms of conventional plant breeding and biotechnologies. Total research investment came to 275.1 million euros, as opposed to 257.0 million euros in 2020-2021, and represents 16.2% of seed activity sales2, which is in line with the average of the previous three fiscal years.

The consolidated operating income stood at 136.3 million euros, an increase compared to the previous fiscal year (127.4 million euros) for all the seeds activities, including Garden Products, resulting in a current operating margin rate of 8.6%, slightly lower by 0.3 percentage points compared with fiscal year 2020-2021.

The share of income from associated companies came to 17.9 million euros, a marked decrease of 8.4 million euros compared with the previous fiscal year, due in particular to a deterioration in the operating performance of AgReliant (North America. Field Seeds) and the impact of hyperinflation, which severely limited the performance of Seed Co in Zimbabwe (Africa. Field Seeds).

The financial result showed a net charge of 33.4 million euros as opposed to 46.9 million euros in 2020-2021, an improvement of 13.5 million euros, mainly due to lower currency exchange losses.

The net charge of income taxes deteriorated by 12.0 million euros, and stood at 25.4 million euros as opposed to 13.4 million euros in 2020-2021, mainly the result of a deterioration in the deferred tax position of 10.6 million euros, partly attributable to hyperinflation in Argentina (under local standards) and in Turkey.

Vilmorin & Cie's total net income came to 95.4 million euros, an increase of 2.0 million euros compared to the previous fiscal year. This is the highest net income since fiscal year 2012-2013. The group share ("attributable to the controlling Company") stood at92.2 million euros.

Net of cash and cash equivalents (321.3 million euros), total financial indebtedness came to 901.1 million euros on June 30, 2022 compared with 867.4 million euros on June 30, 2021. The share of non-current financial indebtedness stood at 1,088.3 million euros, compared with 994.8 million euros the previous year. The group's share of equity stood at1,434.6million euros and minority interests at 48.8 million euros, with a significant increase over the fiscal year, due to the high level of net income and an increase in translation reserves linked to the appreciation of the US dollar.

Thus, compared with the previous fiscal year, the balance sheet structure on June 30, 2022 was marked by a decrease in the ratio of net indebtedness to equity (a gearing of 61%, compared to 65% on June 30, 2021). The leverage ratio as of June 30, 2022 was 2.3x compared with 2.4x as of June 30, 2021, reflecting an improvement in the group's debt reduction capacity.

2022 dividend:Proposal of a dividend of 1.60 euros per share at the upcoming Annual General Meeting of Shareholders, in Auvergne

A dividend of 1.60 euros per share, stable compared to the dividend of the previous fiscal year, will be proposed this year. This corresponds to a distribution rate of 39.8%.

This dividend will be submitted to the vote of the Shareholders by the Board of Directors of Vilmorin & Cie, on the occasion of the Annual General Meeting of Shareholders of December 9, 2022, which will be held in the Auvergne-Rhne-Alpes region, where Limagrain, the parent company and reference shareholder of the Company, is located.

Dividends will be detached on December 13, 2021, with payment on December 15, 2021.

News:A new research partnership concerning pulses in Canada

As explained when sales for the fiscal year 2021-2022 were disclosed, Vilmorin & Cie, through its Field Seeds division, announced the signing of a new partnership with Saskatchewan Pulse Growers3, in July 2022, to set up a joint research and innovation program for pulses, more particularly dry peas and lentils.

This new program, co-financed equally by the two parties, will be based in Saskatoon (Province of Saskatchewan, Canada), where the Limagrain Cereals Research Canada4 joint venture is already established, and will respond directly to the needs of farmers and to major production challenges. Among the targeted goals are resistance to root diseases, increased protein content and, above all, improved yields under variable growing conditions. With the help of a dedicated team, the objective is to bring new expertise to the region in terms of breeding, molecular genetics, treatment of pathologies and field trials.

Canada is the world's largest producer of pulse crops, with more than 2.3 million hectares planted each year5.

Objectives for 2022-2023:

Business growth of between 6% and 8%6and a current operating margin rate of at least 8%

Market conditions for fiscal year 2022-2023 are likely to remain uncertain and fluctuating, due to inflationary pressures resulting, in particular, from the geopolitical context. In this environment, Vilmorin & Cie will continue to play its role as a leading seed company by continuing to strengthen its competitive positions; the Company will pursue its measured investment in research & development, in particular in upstream technologies, while remaining attentive to any opportunity for external growth, in line with its strategic challenges and foundations.

For fiscal year 2022-2023, Vilmorin & Cie has set itself the objective of achieving an increase in consolidated sales of between 6% and 8%6, excluding the positive impact of the EGalim law on sales (which will however be neutral concerning the operating income) 7.

The Company is aiming for a current operating margin rate of at least 8%, impacted by the evolution of its business mix in favor of Field Seeds. This rate will take into account investment into research at a similar level, as a percentage of sales, to that of the two previous fiscal years, and spread evenly between Vegetable Seeds and Field Seeds.

Finally, Vilmorin & Cie is aiming for a contribution from associated companies - mainly AgReliant (North America. Field Seeds), Seed Co (Africa. Field Seeds) and AGT (Australia. Field Seeds) - at least equal to that of fiscal year 2021-2022.

Vilmorin & Cie's commercial prospects in Ukraine-RussiaIn Ukraine, the outlook for the coming fiscal year remains moderate, due to the difficulty of local farmers and distributors to obtain funding and, more generally, the lack of visibility in the region due to the continuing conflict with Russia. Accordingly, the Company expects a level of activity similar to that of fiscal year 2021-2022.

In Russia, thanks to the performance of its sunflower and corn seed varieties in particular, Vilmorin & Cie intends to confirm the momentum observed during the previous fiscal year. Prospects to date are favorable, but their realization remains subject to growing logistical and geopolitical problems, to which the Company is striving to find solutions.

Anthony CARVALHO, Vilmorin & Cie's new Chief Financial Officer

As announced in the press release of its sales for fiscal year 2021-2022, Vilmorin & Cie appointed Anthony CARVALHO to its Executive Committee, on September 14, 2022, as Chief Financial Officer.

Anthony CARVALHO, 33, holds a Master's degree in Information Systems from the Institut Mines-Tlcom SudParis, and also a Master's degree in Audit & Financial Advisory from the University of Paris Dauphine and a Master's degree in Finance from ESSEC. He has significant experience in financial functions, acquired in investment funds and then as Head of the integrated Family Office of the Roullier Group. He also has experience in Audit and Advisory, acquired within Deloitte. Previously, Anthony CARVALHO was, as of September 2021, Chief Financial Officer of the Roullier Group.

Coming disclosures and events

For any further information

Tuesday November 8, 2022*Disclosure of salesfor the first quarter of 2022-2023

Friday December 9, 2022Annual General Meeting of Shareholders

Tuesday December 13, 2022Detachment of the dividends

Thursday December 15, 2022Payment of the dividends

* Disclosure after trading on the Paris stock market.Dates provided as an indication only, and liable to be changed.

Anthony CARVALHOChief Financial Officer

douard ROCHEHead of Financial Communication and Investor Relations

See more here:
Results for the fiscal year on June 30, 2022 - Yahoo Finance

A new way to view colorectal cancer cell differentiation. Secretomics shed light on cells immune response. Targeting the signaling pathway convergence point. Read about papers on these topics recently published in the journal Molecular & Cellular Proteomics.

Colorectal cancer is among the most diagnosed cancers. Its risk factors include genetics, aging and lifestyle choices, such as smoking. Treatment has proved difficult, as this type of cancer is heterogenous and often has an asymptomatic clinical course, resulting in late diagnosis. Identifying reliable biomarkers for diagnosis and disease progression is essential.

Histopathology of colorectal adenocarcinoma with lymphatic invasion.

Research groups previously have determined that altered glycosylation states, in glycosphingolipid particularly, can be associated with malignant transformation in colon cancer. While protein glycosylation in this cancer is studied widely, glycosphingolipid expression of patterns and their contributions to colorectal cancer have yet to be explored.

In a recent study published in Molecular & Cellular Proteomics, Di Wang and collaborators at the Center for Proteomics and Metabolomics at Leiden University Medical Center in the Netherlands performed an in-depth analysis of glycosphingolipid glycans of 22 colorectal cancer cell lines using porous graphitized carbon nanoliquid chromatography coupled with electrospray ionizationmass spectrometry. The authors found that glycosphingolipid expression varies among different cell lines.

They also found that glycosphingolipid expression correlates with relevant glycosyltransferases involved in their biosynthesis as well as with transcription factors implicated in colon differentiation. The authors conclude that this glycomic study provides novel insights into glycosphingolipid glycan regulation for future functional studies in colorectal cancer research.

Hepatocytes cells in the liver that play essential roles in metabolism and detoxification have important secretory and immunological functions. Inflammatory processes produce signals (such as cytokines interleukin-1 and -6) that induce the acute-phase response, which in turn provokes secretion of proteins with immunomodulatory functions to restore homeostasis.

The secretome of a cell or an organism consists of proteins secreted by the endoplasmic reticulumGolgi secretory pathway and other direct or vesicle-based mechanisms. The systematic investigation of secreted proteins by mass spectrometrybased proteomics, however, has faced several challenges, as most approaches use serum-free culture conditions to avoid serum-induced interferences, thus negatively affecting the observable time window, cellular functions and viability.

In a recent article in Molecular & Cellular Proteomics, Sascha Knetch and colleagues at GlaxoSmithKline in Germany developed an interval-based secretomics workflow that determines protein-secretion rates in short serum-free time windows. The authors also implemented a labeling strategy in which they were able to pull up to 11 protein samples into a single mass spectrometry run. This approach allowed for the first comprehensive analysis of time-dependent secretion of liver cell models in response to these pro-inflammatory cytokines.

PI3KmTOR and MEK/MAPK signaling pathways are essential for the regulation of cell survival and other cellular functions. In addition, they are the most frequently dysregulated pathways in cancer.

Some cancer therapies based on kinase inhibitors are effective in tumors that are addicted to prosurvival signals and target individual members within these pathways. This leads to drug resistance and transient responses. To overcome this limitation, researchers are now investigating cotreatments with PI3K/AKT and MEK/MAPK inhibitors; however, the mechanisms leading to sensitivity remain unclear.

In a recent Molecular & Cellular Proteomics article, Maruan Hijazi and collaborators at the Centre for Genomics and Computational Biology at Queen Mary University of London report developing a phosphoproteomics approach based on liquid chromatography tandem mass spectrometry to study the effects of co-treatment on the kinase eEF2K, a convergence point for both pathways.

The authors found that inhibition of eEF2K by siRNA or with a small-molecule inhibitor reversed the anti-proliferative effects of the cotreatment with PI3K plus MEK inhibitors in a cell modelspecific manner. The authors conclude that eEF2K is a key mediator of these pathways and a target for synergistic cotreatment in cancer cells.

See the article here:
From the journals: MCP - ASBMB Today

Rajesh Ramachandran

ASSOCIATE PROFESSOR, IISER, MOHALI

This years Nobel Prize in physiology or medicine has been awarded to Prof Svante Pbo, Director of the Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany. Pbos Nobel journey is somewhat similar to that of another Nobel laureate, Prof Venkatraman Ramakrishnan, a physicist by training, who received the prize in chemistry for his biological studies on ribosomes.

Pbo did research on the biology of adenoviruses and the immune system; he later shifted to genetics and genomics with a special focus on paleoanthropology to obtain the Nobel Prize for an apparently non-medical subject, but with huge medical implications.

Pbo is one of the founders of the scientific branch of paleogenetics, which deals with the characterisation of ancient genomes. Pbo focused on a high-risk, high-reward research where he studied human evolution with a particular focus on the Neanderthal man genome and discovered a previously unknown hominin, termed Denisovan.

Pbo devoted a lot of time and effort to prehistoric caves in search of ancient human remains. His success also emphasises the importance of basic scientific research in the modern world.

The human race originated from Africa and has made several migrations out of Africa, ranging from 50,000 years to 70,000 years ago. Homo sapiens, modern humans, originated in Africa 3,00,000 years ago. Our closest cousins, the Neanderthals, evolved in Europe and western Asia around 4,00,000 years ago and stayed until 30,000 years ago before becoming extinct. The migration of Homo sapiens from Africa occurred 40,000 years ago to West Asia and subsequently to the rest of the world. Homo sapiens and the Neanderthals overlapped in space and time in large parts of Eurasia for thousands of years. The lack of any Neanderthal data post 30,000 years ago had led to speculation of Homo sapiens wiping out the Neanderthals through competition.

But what was our relationship with the extinct Neanderthals? Answering this would require sequencing genomic DNA recovered from archaic specimens. Pbo, while working at the University of Munich, took the challenging task of sequencing ancient mitochondrial DNA from 40,000-year-old bone remains of Neanderthals and found that the Neanderthals were genetically distinct compared to modern humans and chimpanzees.

Pbo further assembled the ever-challenging task of building the Neanderthal genome and published the entire genome in 2010. Genome analysis suggested the independent origin of this human race outside Africa. However, the lineage of their ancestors dates back to Africa. Pbos study revealed the possibility of Homo sapiens interbreeding with Neanderthals, causing their genomic dilution that has left traces of their genome up to 4 per cent in modern-day humans. Genomic comparison studies demonstrated that the most recent common ancestor of Neanderthals and Homo sapiens could have lived around 8,00,000 years ago.

In 2008, Pbo sequenced the DNA from a well-preserved 40,000-year-old finger bone discovered in the Denisova cave in Siberia. The results were sensational as the DNA sequence was unique compared to Neanderthals and present-day humans. Pbo discovered a previously unknown hominin, Denisova. Further studies revealed that gene flow between Denisova and Homo sapiens also occurred. This feature is evident in the human population in Melanesia and other parts of South East Asia, where some individual genomes carry up to 6 per cent Denisova DNA.

Pbos discoveries have led to a novel understanding of the human evolutionary history. When Homo sapiens migrated out of Africa, there were at least two distinct and later extinct hominin populations inhabiting in Eurasia. The Neanderthals lived in western Eurasia, while their contemporary Denisovans thrived in the eastern part of the continent. The final expansion of Homo sapiens outside Africa towards the east was approximately 40,000 years ago; they encountered and interbred with Neanderthals and Denisovans.

Studies and discoveries of Pbo established an entirely new scientific discipline paleogenomics. These lines of evidence further strengthened the scientific communitys understanding of human evolution and migration.

Modern and robust methods for DNA sequence analysis support the view that archaic hominins have interbred with Homo sapiens in Africa. However, the tropical climate in Africa hinders the discovery of ancient DNA preserved from the bone remains of extinct hominins on that continent.

Pbos discoveries on archaic gene sequences of our extinct relatives suggest the influence of modern human physiology. For example, the EPAS1 gene, which confers survival advantage at high altitudes prevalent in present-day Tibetans links back to Denisovans. Several Neanderthal genes are responsible for our immunological response to different infections.

Although Homo sapiens could do complex tasks such as creative tool-making, figurative art, travel across the sea, social organisation and communication, they often lacked the physical endurance and body mass found in Neanderthals. Successful cross-breeding of Homo sapiens and Neanderthals would have allowed better survival in the harsh Eurasian climate. The genetic link between Homo sapiens and our closest extinct relatives, Neanderthals and Denisovans, was unknown until it was established through Pbos epic work. Further to his discoveries, the focus is on analysing the functional implications of differences among Homo sapiens, Neanderthals and Denisovans, with the primary goal of knowing more about how humans evolved as a successful species.

The migration of Homo sapiens out of Africa is an important topic in human evolutionary history. The current belief that our species originated from Africa and spread out to occupy much of Eurasia before colonising the rest of the world is also well supported by Indian studies. Studies by the Indian Statistical Institute and other research laboratories have supported the idea that India was a major corridor for the spread of early humans as early as 1,00,000 years ago, although the exact timeframe of human colonisation in India remains unknown.

A study by the Centre for Cellular and Molecular Biology, Hyderabad, has proven that the Andamanese tribe has closer affinities with the Asian population than with the African population, while the Nicobarese have genetic links to populations throughout Asia today.

Read more from the original source:
From cave-dweller scientist to Nobel laureate - The Tribune India

Animal Genetics Market Outlook 2031

The global animal genetics market was valued at US$ 4.9 Bn in 2021

The global market is projected to grow at a CAGR of 6.7% from 2022 to 2031

The global animal genetics market is anticipated to reach more than US$ 9.1 Bn by the end of 2031

Animal Genetics Market Introduction

Animal genetics is one of the pillars of livestock development. It covers wide areas, from characterization and conservation to genetic improvement, including local, national, regional, and global behavior. The animal genetics industry is seeking alternative solutions in the fight against animal disease and suffering. These include the usage of data and health-driven reproductive indicators and research in breakthrough techniques, including gene editing and immunogenetics.

Gene editing is likely to significantly affect agriculture and animal welfare. Adoption of semen sexing technology and IVF (in vitro fertilization) is rapidly increasing in dairy cows and herds to allow for a more targeted selection of breeding stock to breed the stronger next generation. Possession or availability of such techniques plays an important role in helping farmers accelerate the genetic progress of their herds.

Molecular genetics includes various techniques to generate tailor-made bacterial cultures. One of the techniques is the manipulation of an organism's genome. MG techniques are primarily used in dairy animals in order to achieve new traits through standard breeding strategies.

Read Report Overview @ https://www.transparencymarketresearch.com/animal-genetics-market.html

Increase in Meat Consumption and Rise in Demand for High-quality Proteins to Drive Global Animal Genetics Market

The global population is anticipated to reach 9.1 billion by 2050. According to the FAO of the United Nations, the food output needs to be doubled to feed this population. Therefore, safe, high-quality animal protein must be produced at a low cost. Natural resource depletion, increase in emphasis on food safety, and rise in demand for better nutrition (especially animal protein) are influencing the relevance of livestock treatments and diagnostics. This is expected to drive the demand for high-quality proteins across the globe.

Rise in Pet Ownership and Spending on Companion Animals to Propel Market

The animal healthcare market is witnessing a rise in the ownership of companion animals. The ability to spend money on pets is also rising. According to the American Pet Products Association's 2011-2012 National Pet Owners Survey, 72.9 million households (or 62% of all households) in the U.S. (excluding those with horses) had a companion animal. In terms of spending on companion animals, Asia Pacific and Latin America are the major regions, with a strong growth rate.

Get Customization Research on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=18995

Growth in Demand for Animal Proteins to Augment Live Animals Segment

In terms of product type, the global animal genetics market has been classified into live animals (bovine, porcine, poultry, canine, piscine, and others), genetic material (semen, embryo, and others), and genetic testing. The live animals segment accounted for major share of the global market in 2021. The segment is expected to grow at a rapid pace from 2022 to 2031. Steep rise in demand & consumption of animal proteins and rapid growth in urban population across the world are likely to drive the segment in the near future.

Regional Outlook of Global Animal Genetics Market

North America dominated the global animal genetics market in 2021. The market in the region is projected to grow at a faster CAGR from 2022 to 2031. High penetration of animal genetic companies with advanced technologies also contributed to the region's large market share. The U.S. is a hub for animal breeding organizations, which include startups. Furthermore, key players in the market have headquarters in the U.S. Thus, the U.S. is a prominent market for animal genetics in North America.

Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=18995

Asia Pacific held the second largest share of the global market in 2021. In terms of revenue, the market in the region is likely to grow at a high CAGR from 2022 to 2031. Increase in disposable income and rise in consumption of animal products are driving the market in the region. The region includes well-developed markets such as Japan; high economic growth markets such as China and India; other key countries such as Singapore, Malaysia, Indonesia, South Korea, Thailand, and Taiwan; and key Pacific countries such as Australia and New Zealand.

Analysis of Key Players in Global Animal Genetics Market

The global animal genetics market is fragmented, with the presence of large number of manufacturers that control majority of the share. Mergers and acquisitions and development in product portfolios are key strategies adopted by key players. Leading players operating in the market are Genus plc, CRV Holding B.V., Neogen Corporation, Zoetis, Inc., Groupe Grimaud, Topigs Norsvin, VetGen, Animal Genetics, Inc., and Hendrix Genetics BV.

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA - Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

This release was published on openPR.

Read more from the original source:
Animal Genetics Market - Know the Revenue and Profit-Sources of the Industry - openPR